Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: From standard therapy to novel approaches

Leukemia and Lymphoma

Volumn 51, Issue 8, 2010, Pages 1424-1443

  Engelhardt, Monika ^a   Kleber, Martina ^a   Udi, Josefina ^a   Wsch, Ralph ^a   Spencer, Andrew ^b   Patriarca, Francesca ^c   Knop, Stefan ^d   Bruno, Benedetto ^e   Gramatzki, Martin ^f   Morabito, Fortunato ^g   Kropff, Martin ^h   Neri, Antonino ⁱ   Sezer, Orhan ^c   Hajek, Rom ^j   Bunjes, Donald ^k   Boccadoro, Mario ^e   Straka, Christian ^l   Cavo, Michele ^m   Polliack, Aaron ⁿ   Einsele, Hermann ^d   Palumbo, Antonio ^e   more..

^a UNIVERSITY OF FREIBURG   (Germany)

^b ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF UDINE   (Italy)

^d UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^e UNIVERSITY OF TURIN   (Italy)

^f UNIVERSITY OF KIEL   (Germany)

^g Unit of Geriatrics   (Italy)

^h UNIVERSITY OF MÜNSTER   (Germany)

ⁱ UNIVERSITY OF MILAN   (Italy)

^j UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^k UNIVERSITY HOSPITAL ULM   (Germany)

^l Abteilung Hämatologie und Onkologie   (Germany)

^m UNIVERSITY OF BOLOGNA   (Italy)

ⁿ HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

more..

Author keywords

chemotherapy; molecular targets; Multiple myeloma (MM); novel agents; transplant

Indexed keywords

ALPHA INTERFERON; BORTEZOMIB; CALCIUM; CD19 ANTIBODY; CD20 ANTIBODY; CD27 ANTIGEN; CD28 ANTIGEN; CD56 ANTIGEN; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ERYTHROPOIETIN; ETOPOSIDE; GLUCOCORTICOID; HEMOGLOBIN; IFOSFAMIDE; LENALIDOMIDE; M PROTEIN; MELPHALAN; PARAPROTEIN; PREDNISONE; STEM CELL FACTOR RECEPTOR; THALIDOMIDE; VINCRISTINE;

ALLOGRAFT; ANEMIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BIOLOGY; BLOOD TOXICITY; BONE DISEASE; BONE MARROW; BONE MARROW CELL; CALCIUM BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL INFILTRATION; CLINICAL PRACTICE; CONDITIONING; CONSENSUS; DEATH; DRUG MEGADOSE; DRUG TOLERABILITY; EUROPE; EVIDENCE BASED PRACTICE; HUMAN; INFECTION; JAW OSTEONECROSIS; KIDNEY DISEASE; LOW DRUG DOSE; MICROENVIRONMENT; MORTALITY; MULTIPLE MYELOMA; OSTEOPOROSIS; OVERALL SURVIVAL; PLASMA CELL; PLASMACYTOMA; PLASMACYTOSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RECOGNITION; REMISSION; REVIEW;

ANTINEOPLASTIC AGENTS; CONSENSUS; HUMANS; MULTIPLE MYELOMA; PRACTICE GUIDELINES AS TOPIC; REMISSION INDUCTION; STEM CELL TRANSPLANTATION;

EID: 77955451933     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.487959     Document Type: Review

References (188)

1. Denz U, Haas PS, Wasch R, Einsele H, Engelhardt M. State of the art therapy in multiple myeloma and future perspectives. Eur J Cancer 2006;42:1591-1600.
2. Zlei M, Egert S, Wider D, Ihorst G, Wasch R, EngelhardtM. Characterization of in vitro growth of multiple myeloma cells. Exp Hematol 2007;35:1550-1561.
3. Engelhardt M, Mertelsmann R. 160 years of multiple myeloma: progress and challenges. Eur J Cancer 2006;42: 1507-1509.
4. Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009;113:5412-5417.
5. Engelhardt M, Ihorst G, Behringer D, Finke J, Roth B. Incidence of monoclonal B-cell disease in siblings of patients with multiple myeloma. Haematologica 2006;91:274-276.
6. Engelhardt M, Kleber M, Frydrychowicz A, et al. Superiority of MRI over cenventional radiographs in multiple myeloma. Anticancer Res 2009;29:4745-4750.
7. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet 2009;374:324-339.
8. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-757.
9. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23: 3412-3420.
10. Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008;111: 2962-2972.
11. Engelhardt M, Chevalier N, Kleber M, Spoo A, Schröttner P, Wäsch R. Multiple myeloma: from standards to novel approaches. In: Spyridonidis A, Sakellari I, editors. New insights in hematopoietic cell transplantation. Kerala, India: Research Signpost; 2009:67-88.
12. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-97.
13. Palumbo A, Bringhen S, Petrucci MT, et al. Intermediatedose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004;104:3052-3057.
14. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-1883.
15. Facon T, Mary JY, Hulin C, et al.Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007;370:1209-1218.
16. Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007;356:1110-1120.
17. Zeiser R, Deschler B, Bertz H, Finke J, Engelhardt M. Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome. Bone Marrow Transplant 2004;34:1057-1065.
18. Kleber M, Ihorst G, Deschler B, et al. Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients. Eur J Haematol 2009;83:519-527.
19. Terhorst M, Kleber M, Ihorst G, Engelhardt M. Risk assessment in multiple myeloma (MM) patients (pts): determination of various comorbidity factors, comparison of 4 comorbidity scores (CS) and definition of a novel MMCS to allow improved treatment-decisions and -allocation. Onkologie 2009;32(Suppl. 4):132 (Abstract P488).
20. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncolgy (NCCN GuidelinesTM). Multiple myeloma. Available from: http://www.nccn.org/ professionals/physicianǧls/fǧuidelines.asp.
21. Patriarca F, Petrucci MT, Bringhen S, et al. Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. Eur J Haematol 2009;82:93-105.
22. Dimopoulos MA, Kastritis E, Rosinol L, Blade J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 2008;22:1485-1493.
23. Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2006;132:410-451.
24. Palumbo A, Sezer O, Kyle R, et al. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 2009;23:1716-1730.
25. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. International Myeloma Working Group. Prevention of thalidomideand lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22:414-423.
26. Kleber M, Cybulla M, Bauchmuller K, Ihorst G, Koch B, Engelhardt M. Monitoring of renal function in cancer patients: an ongoing challenge for clinical practice. Ann Oncol 2007;18:950-958.
27. Hoering A, Crowley J, Shaughnessy JD, et al. Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in total therapy protocols. Blood 2009;114:1299-1305.
28. Paiva B, Vidriales MB, Cervero J, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008;112:4017-4023.
29. Rawstron AC, Orfao A, Beksac M, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008;93:431-438.
30. Engelhardt M, Winkler J, Waller C, Lange W, Mertelsmann R, Henschler R. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF. Bone Marrow Transplant 1997;19:529-537.
31. Engelhardt M, Bertz H, Afting M, Waller CF, Finke J. Highversus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection. J Clin Oncol 1999;17: 2160-2172.
32. Engelhardt M, Bertz H, Wasch R, Finke J. Analysis of stem cell apheresis products using intermediate-dose filgrastim plus large volume apheresis for allogeneic transplantation. Ann Hematol 2001;80:201-208.
33. Berger D, Engelhardt M, Mertelsmann R. The blue book. Berlin: Springer; 2009.
34. Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 1992;80:887-890.
35. Einsele H, Langer C, Kropff M, et al. Velcade, intravenous cyclophosphamide and dexamethasone (VCD) induction for previously untreated multiple myeloma (German DSMM XIa Trial). Blood 2009;114(Suppl. 1):59 (Abstract 131).
36. Cavo M, Di Raimondo F, Zamagni E, et al. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. J Clin Oncol 2009;27:5001-5007.
37. Ludwig H, Bladé J, Boccadoro M, et al. Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist 2010;15: 6-25.
38. Palumbo A, Cavallo F, Ben-Yehuda D, et al. A prospective, randomized study of melphalan, prednisone, lenalidomide (MPR) versusmelphalan (200mg/m2) and autologous transplantation (Mel200) in newly diagnosed myeloma patients: an interim analysis. Blood 2009;114(Suppl. 1):148 (Abstract 350).
39. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-1571.
40. Haas PS, Denz U, Ihorst G, Engelhardt M. Thalidomide in consecutive multiple myeloma patients: single-center analysis on practical aspects, efficacy, side effects and prognostic factors with lower thalidomide doses. Eur J Haematol 2008;80:303-309.
41. Dimopoulos MA, Hamilos G, Zomas A, et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J 2004;5:112-117.
42. Wang M, Weber DM, Delasalle K, Alexanian R. Thalidomide- dexamethasone as primary therapy for advanced multiple myeloma. Am J Hematol 2005;79:194-197.
43. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100:3063-3067.
44. Rajkumar SV, Hayman SR, Lacy MQ. Combination therapy with CC-5013 (lenalidomide; RevlimidTM) plus dexamethasone (Rev/Dex) for newly diagnosed myeloma (MM). Blood 2005;106:4050-4053.
45. Kropff M. OPTIMUM trial: randomized comparison of thalidomide versus dexamethasone for relapsed myeloma. Paper presented at XII International MyelomaWorkshop. 26 February-1 March 2009. Washington, DC.
46. Kropff M, Hillengass J, Robak T, Hajek R, Liebisch P. OPTIMUM dose of thalidomide for relapsed multiple myeloma. Blood 2009;114(Suppl. 1): (Abstract 959).
47. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:431-436.
48. Gay F, Hayman SR, Lacy MQ, et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood 2009;114(Suppl. 1):1494 (Abstract 3884).
49. Lacy MQ, Gertz MA, Dispenzieri A, et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 2007;82:1179-1184.
50. Rajkumar SV, Callander N, Fonseca R, et al. Lenalidomide plus high-dose dexamethosone versus lenalidomide plus lowdose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010;11:29-37.
51. Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005;129:776-783.
52. Harousseau JL, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006;91:1498-1505.
53. Harousseau JL, Moreau P. Autologous hematopoietic stemcell transplantation for multiple myeloma. N Engl J Med 2009;360:2645-2654.
54. Bensinger WI. Role of autologous and allogeneic stem cell transplantation in myeloma. Leukemia 2009;23:442-448.
55. Schilling G, Hansen T, Shimoni A, et al. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. Leukemia 2008;22:1250-1255.
56. Catley L, Anderson K. Strategies to improve the outcome of stem cell transplantation in multiple myeloma. Hematol J 2004;5:9-23.
57. Einsele H, Bamberg M, Budach W, et al. A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma. Bone Marrow Transplant 2003;32:593-599.
58. Haas PS, Bauchmuller K, Kuhnemund A, Finke J, Ihorst G, Engelhardt M. Efficacy of diverse high-dose regimens followed by autologous peripheral blood stem cell transplantation in consecutive multiple myeloma patients: a single-centre analysis over a 12-year period. Ann Hematol 2006;85:191-193.
59. Desikan KR, Tricot G, Dhodapkar M, et al. Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone. Bone Marrow Transplant 2000;25: 483-487.
60. Harousseau JL, Attal M, Divine M, et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on autologous transplantation in multiple myeloma. Blood 1995;85:3077-3085.
61. Cunningham D, Powles R, Malpas J, et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol 1998;102:495-502.
62. Attal M, Huguet F, Schlaifer D, et al. Intensive combined therapy for previously untreated aggressive myeloma. Blood 1992;79:1130-1136.
63. Harousseau JL, Milpied N, Laporte JP, et al. Doubleintensive therapy in high-risk multiple myeloma. Blood 1992;79:2827-2833.
64. Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/ m(2) melphalan and 8 Gy total body irradiation plus 140 mg/ m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002;99:731-735.
65. Lenhoff S, Hjorth M, Holmberg E, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 2000;95:7-11.
66. Alegre A, Diaz-Mediavilla J, San-Miguel J, et al. Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM (Grupo Espanol de Trasplante Hematopoyetico-GETH) and PETHEMA. Bone Marrow Transplant 1998;21:133-140.
67. Bjorkstrand BB, Ljungman P, Svensson H, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective casematched study from the European Group for Blood and Marrow Transplantation. Blood 1996;88:4711-4718.
68. Majolino I, Vignetti M, Meloni G, et al. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo. Haematologica 1999;84:844-852.
69. Lee CK, Barlogie B, Zangari M, et al. Transplantation as salvage therapy for high-risk patients with myeloma in relapse. Bone Marrow Transplant 2002;30:873-878.
70. Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998;92:3131-3136.
71. Martínez-López J, Gomez del Castillo J, Mateos Maria V, Alegre A, Garcia-Laraña J. Long term significance of response in multiple myeloma after stem cell transplantation. Blood 2009;114(Suppl. 1):719 (Abstract 1811).
72. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495-2502.
73. Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007;25:2434-2441.
74. Sonneveld P, van der Holt B, Segeren CM, et al. Intermediate- dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial. Haematologica 2007;92:928-935.
75. Matsui W, Huff CA, Wang Q, et al. Characterization of clonogenic multiple myeloma cells. Blood 2004;103:2332-2336.
76. Kuhnemund A, Liebisch P, Bauchmuller K, et al. 'Lightchain escape-multiple myeloma'-an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring. J Cancer Res Clin Oncol 2009;135:477-484.
77. Mandelli F, Avvisati G, Amadori S, et al. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 1990;322:1430-1434.
78. Drayson MT, Chapman CE, Dunn JA, Olujohungbe AB, Maclennan IC. MRC trial of alpha2b-interferon maintenance therapy in first plateau phase of multiple myeloma. MRCWorking Party on Leukaemia in Adults. Br J Haematol 1998;101:195-202.
79. Blade J, San Miguel JF, Escudero ML, et al. Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology). Leukemia 1998;12:1144-1148.
80. Westin J, Rodjer S, Turesson I, Cortelezzi A, Hjorth M, Zador G. Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Cooperative Study Group. Br J Haematol 1995;89: 561-568.
81. Pulsoni A, Avvisati G, Petrucci MT, et al. The Italian experience on interferon as maintenance treatment in multiple myeloma: ten years after. Blood 1998;92:2184-2186.
82. Salmon SE, Crowley JJ, Grogan TM, Finley P, Pugh RP, Barlogie B. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 1994;12: 2405-2414.
83. Peest D, Deicher H, Coldewey R, et al. A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group. Eur J Cancer 1995; 31A:146-151.
84. Salmon SE, Crowley JJ, Balcerzak SP, et al. Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol 1998;16:890-896.
85. Palumbo A, Giaccone L, Bertola A, et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 2001;86: 399-403.
86. Mihelic R, Kaufman JL, Lonial S. Maintenance therapy in multiple myeloma. Leukemia 2007;21:1150-1157.
87. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 2004;104:607-618.
88. Brinker BT, Waller EK, Leong T, et al.Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. Cancer 2006;106:2171-2180.
89. Feyler S, Rawstron A, Jackson G, Snowden JA, Cocks K, Johnson RJ. Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study. Br J Haematol 2007;139:429-433.
90. Martino M, Console G, Callea V, et al. Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patients. Eur J Haematol 2007;78:35-40.
91. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006;108:3289-3294.
92. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006;354:1021-1030.
93. Stewart AK, Chen CI, Howson-Jan K, et al. Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clin Cancer Res 2004;10: 8170-8176.
94. Berenson JR, Crowley JJ, Grogan TM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 2002;99:3163-3168.
95. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22:414-423.
96. Attal M, Marit G, Caillot D, Stoppa AM, Benboubker L. Lenalidomide after autologous transplantation for myeloma: first analysis of a prospective, randomized study of the Intergroupe Francophone Du Myelome (IFM 2005 02). Blood 2009;114(Suppl. 1):220 (Abstract 529).
97. Gay F, Falco P, Crippa C, et al. Sequential approach with bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. Blood 2009;114 (Suppl. 1):1328 (Abstract 3419).
98. McCarthy PL, Stadtmauer EA, Giralt S, Hurd DD, Hassoun H. Phase III intergroup study of lenalidomide (CC-5013) versus placebo maintenance therapy following single autologous stem cell transplant for multiple myeloma (CALGB 100104): initial report of patient accrual and adverse events. Blood 2009;114(Suppl. 1):1327 (Abstract 3416).
99. Minnema MC, van der Holt B, Kersten MJ, Zweegman S, Meijer E, Vellenga E. First interim analysis of HOVON 76: lenalidomide maintenance following non myeloablative allogeneic stem cell transplantation in patients with multiple myeloma. Blood 2009;114(Suppl. 1):901 (Abstract 2285).
100. Kee Lee C, Myint H, Berg M, Kolhouse JF, Robinson W. An outcome study on survival and disease control in patients with high-risk multiple myeloma (MM) for relapse, treated with high-dose melphalan combined with bortezomib for autotransplant followed by post-transplant maintenance with bortezomib and lenalidomide. Blood 2009;114(Suppl. 1): 1322 (Abstract 3404).
101. Sahebi F, Krishnan A, Somlo G, Popplewell L, Parker P, Cai JL. A phase II study of sequential velcade/thalidomide/ dexamethasone (VTD) as maintenance therapy post single autologous peripheral stem cell (PSCT) in patients with multiple myeloma. Blood 2009;114(Suppl. 1):1321 (Abstract 3403).
102. Ladetto M, Pagliano G, Ferrero S, et al. Mayor tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide and dexamethasone in patients with autografted myeloma. J Clin Oncol 2010; 28(12):2077-2084.
103. Jagannath S, Durie BG, Wolf JL, et al. Extended followup of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. Br J Haematol 2009;146:619-626.
104. Rosinol L, Oriol A, Mateos MV, et al. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J Clin Oncol 2007;25:4452-4458.
105. Rajkumar SV, Jacobus S, Callander N, et al. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. Blood 2007;110(Suppl. 1):31a (Abstract 74).
106. Wang L, Siegel D, Kaufman JL, et al. Updated results of bortezomib-naïve patients in PX-171-004, an ongoing openlabel, phase II study of single-agent carfilzomib (CFZ) in patients with relapsed or refractory myeloma (MM). Blood 2009;114(Suppl. 1):127 (Abstract 302).
107. Siegel DW, Wang L, Orlowski RZ, et al. PX-171-004, an ongoing open-label, phase II study of single-agent carfilzomib (CFZ) in patients with relapsed or refractory myeloma (MM); updated results from the bortezomibtreated cohort. Blood 2009;114(Suppl. 1):128 (Abstract 303).
108. Niesvizky R, Wang L, Orlowski RZ, et al. Phase Ib multicenter dose escalation study of carfilzomib plus lenalidomide and low dose dexamethasone (CRd) in relapsed and refractory multiple myeloma (MM). Blood 2009;114(Suppl. 1):128 (Abstract 304).
109. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009;27:5008-5014.
110. Richardson P, Siegel D, Baz R, et al. A phase 1/2 multicenter, randomized, open label dose escalation study to determine the maximum tolerated dose, safety, and efficacy of pomalidomide alone or in combination with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide and bortezomib. Blood 2009; 114(Suppl. 1):126 (Abstract 301).
111. Corradini P, Boccadoro M, Voena C, Pileri A. Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin (IgG)- and IgA-secreting multiple myelomas. J Exp Med 1993;178: 1091-1096.
112. Udi J, Wider D, Wäsch R, Engelhardt M. In vitro testing of standard- and innovative anti-multiple myeloma (MM) substances on MM cell lines (MMCLs) regarding cell toxicity, cell growth and pheotype changes. Onkologie 2009;32(Suppl. 4):228 (Abstract V805).
113. Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003;102:3447-3454.
114. Kroger N, Schwerdtfeger R, Kiehl M, et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002;100:755-760.
115. Bruno B, Giaccone L, Sorasio R, Boccadoro M. Role of allogeneic stem cell transplantation in multiple myeloma. Semin Hematol 2009;46:158-165.
116. Koreth J, Stevenson KE, Kim HT, et al. Bortezomib, tacrolimus, and methotrexate for prophylaxis of graftversus- host disease after reduced-intensity conditioning
117. allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood 2009;114:3956-3959.
118. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006;367:825-831.
119. Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009;27:3664-3670.
120. Wijermans P, Schaafsma M, van Norden Y, Ammerlaan R, Wittebol S, Sinnige H. Melphalan + prednisone versus melphalan + prednisone + thalidomide in induction therapy for multiple myeloma in elderly patients: final analysis of the Dutch Cooperative Group HOVON 49 Study. Blood 2008;112(Suppl. 1):241 (Abstract 649).
121. Kapoor P, Rajkumar SV, Dispenzieri A, et al. Melphalan and prednisone (MP) versus melphalan, prednisone and thalidomide (MPT) as initial therapy for previously untreated elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis of randomized controlled trials. Blood 2009;114(Suppl. 1):254 (Abstract 615).
122. Palumbo A, Bringhen S, Rossi D, et al. Bortezomib, melphalan, prednisone and thalidomide (VMPT) followed by maintenance with bortezomib and thalidomide for initial treatment of elderly multiple myeloma patients. Blood 2009;114(Suppl. 1):58 (Abstract 128).
123. Palumbo A. (). Bortezomib, melphalan, prednisone and thalidomide (VMPT) versus bortezomib, melphalan and prednisone (VMP) in elderly newly diagnosed myeloma patients: a prospective, randomized, phase III study. Presented at 14th Congress of the European Hematology Association. 4-7 June 2009. Berlin.
124. San Miguel J, Schlag R, Khuageva N, et al. VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-917.
125. Palumbo A, Falco P, Corradini P, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol 2007;25:4459-4465.
126. Palumbo A, Dimopoulos MA, Delforge M, et al. A phase III study to determine the efficacy and safety of lenalidomide in combination with melphalan and prednisone (MPR) in elderly patients with newly diagnosed multiple myeloma. Blood 2009;114(Suppl. 1):253 (Abstract 613).
127. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-2520.
128. San Miguel J. Relapse/refractory myeloma patient: potential treatment guidelines. J Clin Oncol 2009;27:5676-5677.
129. Ross JR, Saunders Y, Edmonds PM, et al. A systematic review of the role of bisphosphonates in metastatic disease. Health Technol Assess 2004;8:1-176.
130. Terpos E, Sezer O, Croucher PI, et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 2009;20:1303-1317.
131. Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007;25:2464-2472.
132. Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002; 20:3719-3736.
133. Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev 2002;(2):CD002068.
134. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate- associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005;104:83-93.
135. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144: 753-761.
136. AAE. American Association of Endodontists position statement. Available from: http://www.aae.org/dentalpro/ guidelines.htm.
137. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonaterelated osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 2009;67(Suppl.):2-12.
138. Zervas K, Verrou E, Teleioudis Z, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 2006;134:620-623.
139. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004;100: 2613-2621.
140. Dimopoulos MA, Roussou M, Gavriatopoulou M, et al. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. Clin Lymphoma Myeloma 2009;9:302-306.
141. Terpos E, Katodritou E, Tsiftsakis E, et al. Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration. Haematologica 2009;94:372-379.
142. Kleber M, Haas PS, Koch B, Engelhardt M. Sensitive detection of renal function in multiple myeloma (MM) patients (pts) receiving lenalidomide treatment. Onkologie 2009;32(Suppl. 4):207 (Abstract P741).
143. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20: 4083-4107.
144. Prutchi-Sagiv S, Golishevsky N, Oster HS, et al. Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease? Br J Haematol 2006;135:660-672.
145. Engelhardt M, Thierry V, Spoo A. Hämatopoetischen Wachstumsfaktoren. Leitlinien der DGHO Therapieempfehlungen. Available from: www.dgho.de.
146. Antin JH. Clinical practice. Long-term care after hematopoietic- cell transplantation in adults. N Engl J Med 2002; 347:36-42.
147. Berger D, Engelhardt M, Mertelsmann R. A concise manual of hematology and oncology. Berlin: Springer; 2008.
148. Engelhardt M, Haas PS, Theilacker C, et al. Prevention of infections and thromboses after splenectomy or because of functional loss of the spleen. Dtsch Med Wochenschr 2009;134:897-902.
149. Engelhardt M, Haas PS, Heimpel H, Kern WV. Prävention von Infektionen und Thrombosen nach Splenektomie oder funktioneller Asplenie - Leitlinien Splenektomie der DGHO. Available from: www.dgho.de/cms.php?id=705 2009.
150. Harousseau JC, Avet-Loiseau H, Attal M, et al. High complete and very good partial response rates with bortezomib- dexamethasone as induction prior to ASCT in newly diagnosed patients with high-risk myeloma: results of the IFM2005-01 phase 3 trial. Blood 2009;114(suppl. 1);149 (Abstract 353).
151. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-866.
152. Loffler D, Brocke-Heidrich K, Pfeifer G, et al. Interleukin- 6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 2007;110:1330-1333.
153. Pichiorri F, Suh SS, Ladetto M, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA 2008;105:12885-12890.
154. Lionetti M, Biasiolo M, Agnelli L, et al. Identification of microRNA expression patterns and definition of a micro- RNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood 2009;114:e20-e26.
155. Gutierrez NS, Misiewicz-Krzeminska ME, Delgado I, et al. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia 2010;24:629-637.
156. Roccaro AM, Sacco A, Thompson B, et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 2009;113:6669-6680.
157. Kuehl WM, Bergsagel PL. Early genetic events provide the basis for a clinical classification of multiple myeloma. Hematology Am Soc Hematol Educ Program 2005:346-352.
158. Ishii Y, Pirkmaier A, Alvarez JV, et al. Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model. J Natl Cancer Inst 2006;98:1238-1247.
159. Wäsch R, Denz U, Engelhardt M. Proteasome inhibition as a new therapeutic concept. Tumor Diagn Ther 2006;27:215-220.
160. Ngo TB, Felthaus J, Ihorst G, Engelhardt M, Wäsch R. Monitoring bortezomib therapy in multiple myeloma: screening of cyclin D1 overexpression as a potential prognostic marker for response to treatment. J Clin Oncol 2008;26(Suppl.): Abstract 8614.
161. Schüler JB, Wider D, Fiebig HH, Engelhardt M. Antitumor activity in a human multiple myeloma xenograft model using sorafenib and bortezomib in mono- and combined therapy. Onkologie 2009;32(Suppl. 4):135 (Abstract P494).
162. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008;111:2521-2526.
163. Engelhardt M, Spoo A, Thierry V, Kleber M, Neubauer W, Wäsch R. Hematopoietic growth factors: much ado about something? In: Spyridonidis A, Sakellari I, editors. New insights in hematopoietic cell transplantation. Kerala, India: Research Signpost; 2009; p. 171-195
164. Ludwig H, Hajek R, Tothova E, et al. Thalidomidedexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood 2009;113: 3435-3442.
165. Zonder JA, Crowley J, Hussein MA, Bolejack V, Moore DF, Whittenberger BR. Superiority of lenalidomide (Len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG trial S0232. Blood 2007;110(Suppl. 1):32a (Abstract 77).
166. Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Williams M. Randomized trial of lenalidomide plus highdose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the Eastern Cooperative Oncology Group: analysis of response, survival, and outcome. J Clin Oncol 2008;26(Suppl.): Abstract 8504.
167. Palumbo A, Bringhen S, Liberati AM, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 2008;112:3107-3114.
168. Waage A, Gimsing P, Juliusson G, Turosson I, Fayers P. Melphalan-prednisone-thalidomide to newly diagnosed patients with multiple myeloma: a placebo controlled randomized phase 3 trial. Blood 2007;110(Suppl. 1):32a (Abstract 78).
169. Guldbrandsen N, Waage A, Gimsing P, Turesson I, Juliusson G, Ablidgaard N. A randomized placebo controlled study with melphalan/prednison vs melphalan/prednison/ thalidomide: quality of life and toxicity. Haematologica 2008;93(Suppl.): Abstract 0209.
170. Mateos M, Oriol A, Martinez J, Cibeira MT, de Paz R, Terol MJ. Bortezomib (Velcade)-melphalan-prednisone (VMP) versus Velcade-thalidomide-prednisone (VTP) in elderly untreated multiple myeloma patients: Which is the best partner for Velcade: an alkylating or an immunomodulator agent? Blood 2008;112(Suppl. 1):243 (Abstract 651).
171. Palumbo A, Bringhen S, Rossi D, Magarotto V, Di Raimondo F, Ria R. A prospective, randomized, phase III study of bortezomib, melphalan, prednisone and thalidomide (VMPT) versus bortezomib, melphalan and prednisone (VMP) in elderly newly diagnosed myeloma patients. Blood 2008;112(Suppl. 1):243 (Abstract 652).
172. Cavo M, Patriarca F, Tacchetti P, Galli M, Perrone G, Petrucci MT. Bortezomib (Velcade)-thalidomide-dexamethasone (VTD) vs thalidomide- dexamethasone (VD) in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM). Blood 2007;110(Suppl. 1):30A (Abstract 73).
173. Dimopoulos MA, Zervas K, Kouvatseas G, et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001;12:991-995.
174. Kropff MH, Lang N, Bisping G, et al. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol 2003;122:607-616.
175. Davies FE, Wu P, Jenner M, Srikanth M, Saso R, Morgan GJ. The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. Haematologica 2007;92:1149-1150.
176. Offidani M, Corvatta L, Marconi M, et al. Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study. Haematologica 2006;91:133-136.
177. Hussein MA, Baz R, Srkalovic G, et al. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreasedfrequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clin Proc 2006;81:889-895.
178. Terpos E, Kastritis E, Roussou M, et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia 2008;22: 2247-2256.
179. Reece DE, Rodriguez GP, Chen C, et al. Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol 2008;26:4777-4783.
180. Richardson PG, Jagannath S, Jakubowiak A, Lonial S, Raje N, Alsina M. Lenalidomide, bortezomib, and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (MM): encouraging response rates and tolerability with correlation of outcome and adverse cytogenetics in a phase II study. Blood 2008;112(Suppl. 1):614 (Abstract 1742).
181. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-2498.
182. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007;25:3892-3901.
183. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123-2132.
184. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133-2142.
185. Sirohi B, Powles R. Multiple myeloma. Lancet 2004; 363(9412):875-887.
186. Harousseau JL, Moreau P. Autologoug homatopoietic stemcell transplantation for multiple myeloma. N Engl J Med 2009;360(25):2645-2654.
187. Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002;2(12):927-937.
188. Hideshima T, Mitsiades C, Tonon G, et al. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007; 7(8):585-598.